Regulatory non-coding RNAs in acute myocardial infarction

Yuan Guo, Fei Luo, Qiong Liu, Danyan Xu *

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

Received: July 16, 2016; Accepted: October 9, 2016

Introduction

NcRNAs modulate angiogenesis in ischaemic areas
NcRNAs mediate cardiomyocyte apoptosis
- Non-beneficial miRNAs in cardiomyocyte apoptosis
- Protective miRNAs in cardiomyocyte apoptosis
LncRNAs and circRNAs in cardiomyocyte apoptosis
NcRNAs regulate inflammation around infarct areas

Abstract

Acute myocardial infarction (AMI) is one of the most common cardiovascular diseases that leads to high mortality and morbidity globally. Various therapeutic targets for AMI have been investigated in recent years, including the non-coding RNAs (ncRNAs). NcRNAs, a class of RNA molecules that typically do not code proteins, are divided into several subgroups. Among them, microRNAs (miRNAs) are widely studied for their modulation of several pathological aspects of AMI, including cardiomyocyte apoptosis, inflammation, angiogenesis and fibrosis. It has emerged that long ncRNAs (lncRNAs) and circular RNAs (circRNAs) also regulate these processes via interesting mechanisms. However, the regulatory functions of ncRNAs in AMI and their underlying functional mechanisms have not been systematically described. In this review, we summarize the recent findings involving ncRNA actions in AMI and briefly describe the novel mechanisms of these ncRNAs, highlighting their potential application as therapeutic targets in AMI.

Keywords: acute myocardial infarction • microRNAs • long non-coding RNAs • circular RNAs • apoptosis • inflammation • angiogenesis • fibrosis

Introduction

AMI is the most severe cardiovascular event, resulting in high morbidity and mortality worldwide. Atherosclerosis-induced coronary artery luminal occlusion and plaque rupture is the most common cause of AMI, which is characterized by endothelial injury, lipid accumulation and the formation of atherosclerotic plaque. Cardiomyocyte necrosis and apoptosis with subsequent excessive inflammation are the main causes of myocyte injury and loss in the pathological process of AMI [1]. Yet, angiogenesis in the ischaemic area promotes cardiomyocyte survival [2]. Eventually, the extent of infarcted ventricular remodelling by fibrosis determines cardiac function and prognosis. Therefore, approaches that inhibit cell death and ventricular fibrosis, regulate inappropriate inflammatory response and promote angiogenesis after AMI are promising therapeutic approaches for improving the prognosis of patients with AMI.

Keywords: acute myocardial infarction • microRNAs • long non-coding RNAs • circular RNAs • apoptosis • inflammation • angiogenesis • fibrosis

*Correspondence to: Danyan XU,
E-mail: xudanyan02@sina.com
Apoptosis is a highly regulated process that is activated by various factors, which is generally viewed as an uncontrolled process in AMI. Cardiomyocyte necrosis is a key cellular event in infarct cardiomyopathy, and it is closely related to the ratio of B-cell lymphoma 2 (Bcl-2) and the pro-apoptotic effector Bcl-2-associated X protein (BAX). When the pro-apoptotic effector disrupts the mitochondrial membrane, apoptosis occurs. Regulating the levels of certain miRNAs after AMI may be helpful for limiting tissue injury, promoting neovascularization, and controlling ventricular remodelling, subsequently improving long-term prognosis.

LncRNAs are a diverse class of heterogeneous transcribed RNA molecules ranging from 200 to 100,000 nucleotides in length. As a newly identified ncRNA in function, the common feature of lncRNAs is that they do not act as vehicles for protein translation [9]. Similarly, lncRNAs function as regulators of protein expression. As lncRNAs are also essential for correct and timely regulation of protein expression, they are not only considered to perform functions during the development of an organism, but also play roles in various physiological and pathological conditions, including AMI, even though very little is known of them at present. Furthermore, as lncRNAs are more likely to be expressed in a tissue-specific or cell-type-specific manner and can bind to miRNAs to communicate with other RNA targets, lncRNAs have garnered much research attention [10].

CircRNAs, newly discovered endogenous ncRNAs in function, are involved in an area of much research activity because they lack an open end, preventing conventional RNA degradation pathways and acting as more stable RNA molecules [11, 12]. CircRNAs are also expressed in a manner specific to tissue and developmental stage. Similarly, as potential gene regulators, circRNAs modulate many disorders. To date, the function of circRNAs in disease processes has seldom been studied; only a few circRNAs have been proven to play or potentially play cardiovascular-related roles by acting as molecular sponges targeting miRNAs. Additional exploration of circRNA function will further describe an emerging new factor in the pathological processes of AMI.

Previous studies have reported the importance of both miRNAs and lncRNAs in regulating the pathological processes of AMI; the newly identified functional non-coding transcripts, circRNAs, have emerged as modulators of AMI. However, most recently identified ncRNAs and their communication in AMI have not been comprehensively reviewed. Accordingly, we have summarized these ncRNAs and their implicated interactions in modulating cardiomyocyte apoptosis, inflammation, angiogenesis, and fibrosis after the acute setting to gain insight into their therapeutic potential in AMI.

NcRNAs mediate cardiomyocyte apoptosis

Cardiomyocyte necrosis is a key cellular event in infarct cardiomyopathy, which is generally viewed as an uncontrolled process in AMI. Apoptosis is a highly regulated process that is activated via death receptors in the plasma membrane and that mainly occurs in ischaemic areas. The mitochondria-dependent apoptotic pathway is closely controlled by the ratio of B-cell lymphoma 2 (Bcl-2) and the pro-apoptotic effector Bcl-2-associated X protein (BAX). When the pro-apoptotic effector disrupts the mitochondrial membrane, apoptosis occurs. Furthermore, extrinsic receptor-mediated apoptosis is engaged when certain death receptor ligands, such as FAS ligand and tumour necrosis factor-α (TNF-α), bind their death receptors on the plasma membrane. Then, caspase-8 is activated in a manner Fas-associated protein with death domain (FADD)-dependent manner. The effector caspases converge on these two pathways. The pro-apoptotic pathway is counteracted by a series of anti-apoptotic mediators, including the Phosphoinositide-3-kinase (PI3K)/AKT pathway. Numerous miRNAs regulate cardiomyocyte apoptosis (Fig. 1A).

Non-beneficial miRNAs in cardiomyocyte apoptosis

Some non-beneficial miRNAs decrease the Bcl-2/BAX ratio to promote apoptosis. MiR-15a and miR-15b are up-regulated in response to cardiac ischaemia/reperfusion injury and are involved in myocardial apoptosis by targeting Bcl-2 and the caspase signalling pathway [13]. By contrast, miR-15 inhibition is protective against cardiac injury after MI [14]. Forced expression of miR-497 induced apoptosis in neonatal rat cardiomyocytes, but silencing miR-497 using a miR-497 sponge significantly reduced apoptosis; this process was also involved in reducing the expression of the anti-apoptosis gene BCL-2 [15]. Similarly, miR-24 increases cardiovascular apoptosis in the infarcted myocardium [16]. In mice, local adenovirus-mediated over-expression of miR-24 increased the percentage of apoptotic cardiomyocyte nuclei by 2.2-fold. In addition, miR-24 exerts its pro-apoptotic function by targeting the pro-apoptotic gene BCL2-like 11 apoptosis facilitator (BIM) that in turn represses Bcl-2 expression [17]. MiR-208a also has pro-apoptotic effects on ischaemic cardiomyocytes, which are related to the increased expression of the pro-apoptosis gene BAX in ischaemic cardiomyocytes [18]. MiR-34a has also been confirmed as an important pro-apoptosis regulator in AMI [19]; it is increased after ischaemia and exerts its pro-apoptosis function by negatively regulating the anti-apoptotic protein aldehyde dehydrogenase-2 (ALDH2), which also decreases the Bcl-2/BAX ratio [20].

Several other miRNAs promote cardiomyocyte apoptosis after AMI by directly targeting the caspase family. Wang et al. [21] demonstrated that miR-874 is involved in H₂O₂-induced cardiomyocyte death by increasing caspase-8 after MI. The authors further confirmed the apoptosis-promoting function of miR-874 using a miR-874 antagonist that significantly attenuated H₂O₂-induced cell death. MiR-155 deficiency prevented ischaemia/reperfusion injury-induced apoptosis in an AMI mouse model [15]. Furthermore, Eisenhardt et al. [22] found that miR-155 aggravated apoptosis post-AMI by increasing the expression of the apoptosis-related caspase-3.

MiR-92a promoted apoptosis in the heart after MI, and treatment with antagoniR-92a to inhibit miR-92a in vitro reversed this process. Unfortunately, the antagoniR-92a-induced reduction in cardiomyocyte apoptosis was not observed in vivo, suggesting that an indirect mechanism mediates the anti-apoptotic activity of antagoniR-92a in vivo [8]. Overall, inhibiting these miRNAs may be new therapeutic approaches in AMI.
Protective miRNAs in cardiomyocyte apoptosis

The PI3K/AKT pathway is the main signalling pathway for inhibiting apoptosis that is consistently activated with activation of the pro-apoptotic pathway after AMI. Several miRNAs protect cardiomyocytes against apoptosis after AMI by activating PI3K and its downstream regulators. MiR-210 inhibited apoptosis in mice after MI, and miR-210 overexpression prevented cardiomyocyte apoptosis by down-regulating protein tyrosine phosphatase-1B that subsequently activated the PI3K/AKT pathway [23]. MiR-214 is a newly identified miRNA that inhibits cardiomyocyte apoptosis. Overexpression of miR-214 in an AMI rat model decreased the size of the infarcted area, improved heart function and haemodynamic status and inhibited left ventricular remodelling. The miR-214-mediated protective mechanism is based on the repression of phosphatase and tensin homolog (PTEN), which acts as a PI3K inhibitor [24]. In an AMI mouse model, overexpressing miR-1 in embryonic stem cells and transplanting them into infarcted myocardium inhibited cardiomyocyte apoptosis and improved cardiac function after 4-week treatment, which was related to reduced PTEN levels and caspase-3 activity [25, 26]. Similarly, miR-21 was involved in trimetazidine-induced anti-apoptosis during ischaemia/reperfusion injury, and increased miR-21 expression inhibited cardiomyocyte apoptosis [27]. Forced expression of miR-21 up-regulated PI3K/AKT activity by suppressing PTEN expression and increasing the Bcl-2/BAX ratio, which in turn reduced caspase-3 expression and finally counteracted the apoptotic effect [28].

Another mechanism of the miR-21-induced anti-apoptosis effect in H2O2-mediated cardiomyocytes is directly inhibiting pro-apoptotic protein poly ADP-ribose polymerase (PARP), which favours cardiomyocyte survival and inhibited apoptosis. More interestingly, it was recently reported that miR-499 protects cardiomyocytes from H2O2-induced apoptosis and rat AMI models by suppressing expression of the pro-apoptotic protein PARP and phosphofurin acidic cluster sorting protein 2, thereby blocking Bid expression and BID mitochondrial translocation [34, 35].

Other miRNAs also directly target the caspase family. Dakhlallah et al. [36] transfected mesenchymal stem cells with miR-133a and found that it prevented apoptosis by directly targeting apoptotic protease-activating factor-1, which down-regulated caspase-9 and caspase-3 expression. Lu et al. [37] found that MI induced myocardial apoptosis and increased caspase-3/7 and caspase-8 activity by 105.6% and 71.3%, respectively, when compared with sham controls, while lentivirus transfection of miR-130a overexpression markedly reduced caspase-3/7 and caspase-8 activity by 22.9% and 30.8%, respectively, as compared with the controls. Ding et al. [38]...
reported that miR-149 contributed to inhibition of apoptosis after MI by regulating the pro-apoptotic protein PUMA, which in turn activated caspase-9 to promote apoptosis. Hence, activating these miRNAs is a promising target for treating AMI.

**LncRNAs and circRNAs in cardiomyocyte apoptosis**

Recently, some lncRNAs and circRNAs were identified as vital biomarkers and promising therapeutic targets in AMI [39, 40] (Table 1 and Fig. 1B). The circulating lncRNA urothelial carcinoma-associated 1 (UCA1) was down-regulated within 3 days after the onset of AMI [41]. Microarray analysis of MI mice showed that two lncRNAs, MI-associated transcript 1 and 2, were significantly up-regulated five-fold and 13-fold, respectively, after MI [42]. Moreover, myosin heavy chain-associated RNA transcripts (MHRT), a heart-specific lncRNA, were significantly elevated in the blood of patients with AMI as compared with healthy controls (P < 0.05). In a H2O2-induced neonatal rat cardiac myocyte injury model, MHRT was also up-regulated in injured cardiac myocytes, and short interfering RNA knock-down of the Mhrt gene led to more apoptotic cells than in the non-target control (P < 0.01), indicating that MHRT is not only a biomarker of ischaemic cardiomyocytes but also a protective lncRNA for cardiomyocytes and a promising therapeutic target of AMI [43].

In addition, other lncRNAs interact with miRNAs to exert their apoptotic inhibitory function. MiR-188-3p inhibited autophagy under pathological conditions by targeting autophagy-related protein 7. Wang et al. [44] found that the lncRNA autophagy-promoting factor regulated autophagic cell death by down-regulating miR-188-3p, thereby promoting autophagy after MI. Cardiac apoptosis-related lncRNA (CARL) suppressed mitochondrial fission and apoptosis by decreasing endogenous miR-539 levels by acting as a sponge, which in turn up-regulated prohibitin 2 expression to inhibit apoptosis [45]. miRNA-103/107 and the lncRNA H19 also mediate cardiomyocyte survival after AMI. H19 bound directly to miR-103/107, suppressing receptor-interacting serine/threonine protein kinase (RIPK)1/RIPK3 and FADD-dependent death in foetal cardiomyocyte-derived H9C2 cells and in an MI mice model [46]. The lncRNA necrosis-related factor (NRF) targets miR-873 and RIPK1/RIPK3 to regulate cardiomyocyte death. An endogenous sponge RNA, NRF repressed miR-873 expression, which in turn increased RIPK1/RIPK3 and cardiomyocyte death [47]. Thus, these lncRNAs are potential therapeutic targets of AMI by inhibiting cardiomyocyte death.

The circRNA cerebellar degeneration-related protein 1 transcript (CDR1as) has 63 conserved binding sites for miR-7, by which CDR1as could function as an miR-7 sponge to regulate post-transcriptional gene expression [48]. Intriguingly, Geng et al. [49] recently reported the CDR1as/miR-7a pathway in cardiomyocytes and explored the underlying function of miR-7a in protection against AMI. They found that CDR1as and miR-7a were both up-regulated in MI mice or cardiomyocytes under hypoxia treatment. However, overexpression of CDR1as in vivo increased cardiac infarct size, while miR-7a overexpression reversed these changes. Furthermore, CDR1as functioned as a powerful miR-7a sponge in myocardial cells, and miR-7a protected cardiomyocytes from injury after MI by inhibiting

---

**Table 1** Long non-coding RNAs as biomarkers in acute myocardial infarction

| LncRNAs                | Regulation after AMI | Relation to other biomarkers                                                                 |
|------------------------|----------------------|-------------------------------------------------------------------------------------------------|
| Yan et al. [41]        | UCA1                 | Down-regulation                                                                               | Inversely related to miR-1 level                                                          |
| Zangrando et al. [42]  | MIRT1/MIRT2          | Up-regulation                                                                                 | Negatively correlated with infarct size; positively correlated with EF value               |
| Zhang et al. [43]      | MHRT                 | Up-regulation                                                                                 | Inversely related to cardiomyocyte apoptosis                                              |
| Vausort et al. [56]    | ANRIL                | Down-regulation                                                                               | Positively correlated to lymphocytes and monocytes; negatively related to MMP9, WBC, neutrophils, platelets |
| Vausort et al. [56]    | MIAT                 | Down-regulation                                                                               | Positively related to lymphocytes; negatively related to neutrophils, platelets           |
| Vausort et al. [56]    | MALAT1               | Up-regulation                                                                                 | Negatively related to platelets                                                           |
| Vausort et al. [56]    | aHIF                 | Up-regulation                                                                                 | Positively related to WBC, neutrophils CRP, MMP9, TIMP1; negatively related to lymphocytes |
| Qu et al. [80]         | NONNMUT022554        | Up-regulation                                                                                 | Positively correlated with fibrosis gene expression                                       |

ANRIL, cyclin-dependent kinase inhibitor 2 antisense RNA 1; aHIF, hypoxia-inducible factor 1A antisense RNA 2; CRP, C-reactive protein; EF, ejection fraction; MIRT1, MI-associated transcript 1; MIRT2, MI-associated transcript 2; MIAT, myocardial infarction-associated transcript; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MMP9, matrix metalloproteinase 9; TIMP1, tissue inhibitor of metalloproteinase 1; UCA1, urothelial carcinoma-associated 1; WBC, white blood cell.
the expression of the pro-apoptotic gene poly ADP-ribose polymerase (PARP) and SP1. This indicates that CDR1as may be a promising anti-apoptosis target.

**NcRNAs regulate inflammation around infarct areas**

Cardiac cell death after ischaemia subsequently induces inflammatory cascades. Proper inflammatory reaction helps to clear cellular debris and trigger repair mechanisms after AMI, while excessive inflammation is a critical factor in aggravating cardiomyocyte injury and death. Therefore, modulating excessive inflammatory response is essential for preventing cardiomyocyte death [50]. Some miRNAs play critical roles in reducing the inflammatory response after AMI (Table 2).

The inflammatory response is mainly involved in monocyte cell migration and the production of a cluster of proinflammatory cytokines, which then initiate a cascade reaction. The overexpression of miR-150 in mice was critical for monocyte migration and proinflammatory cytokine production, resulting in cardioprotective effects against AMI injury. This was related to miR-150 inhibition of chemokine receptor 4 and subsequently reduced inflammatory Ly-6C\textsuperscript{high} monocyte invasion after AMI [51]. Furthermore, the inflammation-related miR-155 was down-regulated by approximately 60% in patients with acute coronary syndrome, which was consistent with the expression of interleukin-17A in peripheral blood mononuclear cells, suggesting that it is essential for T helper cell differentiation [52]. A similar study reported that, in an AMI mouse model, miR-155 significantly increased TNF-\(\alpha\), IL-1b and CD105 expression and leucocyte infiltration after AMI, and that miR-155 deficiency prevented ischaemia/reperfusion injury-induced tissue necrosis and attenuated inflammatory cell infiltration [22].

There is evidence that the inflammation-related miR-146a and miR-21 are increased by approximately twofold in patients with acute coronary syndrome [52]. Liu et al. [53] found that miR-146a and miR-21 were positively related with MI, which was consistent with the expression of interleukin-17A in peripheral blood mononuclear cells, suggesting that it is essential for T helper cell differentiation [52]. A similar study reported that, in an AMI mouse model, miR-155 significantly increased TNF-\(\alpha\), IL-1b and CD105 expression and leucocyte infiltration after AMI, and that miR-155 deficiency prevented ischaemia/reperfusion injury-induced tissue necrosis and attenuated inflammatory cell infiltration [22].

Table 2 MicroRNAs regulated inflammation in acute myocardial infarction

| NcRNAs       | Function                  | Targets                                      | Modulation       |
|--------------|---------------------------|----------------------------------------------|------------------|
| Liu et al. [51] | miR-150                  | Inhibit inflammation                         | Increase expression |
| Yao et al. [52] | miR-155                  | Promote inflammation                        | Inhibit expression |
| Eisenhardt et al. [22] | miR-155                | Promote inflammation                        | Inhibit expression |
| Ibrahim et al. [54] | miR-146a                | Inhibit inflammation                         | Increase expression |
| Toldo et al. [55] | miR-21                   | Inhibit inflammation                         | Increase expression |

CXCR4, chemokine receptor 4; IL-1\(\beta\), interleukin-1\(\beta\); IRAK1, interleukin-1 receptor-associated kinase 1; TNF-\(\alpha\), tumour necrosis factor-\(\alpha\); TRAF6, tumour necrosis factor receptor-associated factor 6.

**NcRNAs modulate angiogenesis in ischaemic areas**

Angiogenesis is a critical component in post-AMI early tissue repair that also participates in limiting the infarct size and reducing myocardial apoptosis. MiRNAs also modulate angiogenesis (Fig. 2 and Table 3). MiR-92a is the most widely studied miRNA for inhibiting angiogenesis after AMI. Bellera et al. [57] demonstrated that a single intracoronary administration of antagoniR-92a encapsulated in specific microspheres inhibited miR-92a, resulting in significant vessel growth in a local, selective and sustained manner in a pig model of AMI. Bonauer et al. [8] reported that miR-92a controlled blood vessel growth in an MI mouse model by decreasing integrin \(\alpha\)5; systemic administration of antagoniR-92a enhanced blood vessel growth and functional recovery of damaged tissue. Similarly, Hinkel et al. [58] found that local delivery of locked nucleic acid (LNA)-modified antisense miR-92a directed against miR-92a expression significantly reduced infarct size and improved the recovery of cardiac function.
function in pigs after MI by targeting integrin α5. Consequently, miR-92a may serve as a valuable therapeutic target in the ischaemic disease setting.

Several other miRNAs, including miR-26a, miR-24, miR-34c and miR-375, are involved in suppressing angiogenesis in AMI. MiR-26a overexpression in an AMI mouse model and in human subjects with acute coronary syndrome attenuated angiogenesis. By contrast, miR-26a inhibitor induced angiogenesis by inhibiting bone morphogenic protein (BMP)/SMAD1 signalling, thereby reducing myocardial infarct size [59]. Moreover, direct antagonists against miR-24 or local adenovirus-mediated miR-24 decoy delivery improved recovery after AMI in mice. MiR-24 inhibition increased blood vessels in infarcted myocardium by increasing endothelial nitric oxide synthase (eNOS) and decreasing the pro-angiogenic p21 protein-Cdc42/Rac-activated kinase 4 (PAK4) and globin transcription factor binding protein 2 (GATA2) [16, 17]. High glucose-induced miR-34c expression impaired angiogenic activity after MI by reducing stem cell factor (SCF) and increasing Krüppel-like factor 4 (KLF4) and plasminogen activator inhibitor-1 (PAI-1) [60]. MiR-375 also inhibits angiogenesis after MI; IL-10-induced miR-375 decrease exerted a pro-angiogenic effect by up-regulating 3-phosphoinositide-dependent protein kinase-1 (PDK-1) [61]. Accordingly, inhibiting these harmful miRNAs after AMI may be a promising therapeutic target and may improve the prognosis after acute settings.

---

**Table 3** Non-coding RNAs regulated angiogenesis in acute myocardial infarction

| NcRNAs   | Function               | Targets                              | Modulation     |
|----------|------------------------|--------------------------------------|----------------|
| Bonauer et al. [8] | miR-92a | Inhibit angiogenesis | Decrease ITGA5 | Inhibit expression |
| Hinkel et al. [58] | miR-92a | Inhibit angiogenesis | Decrease ITGA5 | Inhibit expression |
| Icli et al. [59] | miR-26a | Inhibit angiogenesis | Inhibit BMP/SMAD1 | Inhibit expression |
| Meloni et al. [17] | miR-24 | Inhibit angiogenesis | Decrease eNOS, increase PAK4, GATA2 | Inhibit expression |
| Kang et al. [60] | miR-34c | Inhibit angiogenesis | Decrease SCF increase KLF4, PAI-1 | Inhibit expression |
| Garikipati et al. [61] | miR-375 | Inhibit angiogenesis | Negatively regulate PDK-1 | Inhibit expression |
| Huang et al. [63] | miR-126 | Promote angiogenesis | Up-regulation of VEGF, bFGF and DLL-4 | Increase expression |
| Wang et al. [64] | miR-126 | Promote angiogenesis | Promoting VEGF, FGF repressing SPRED1 | Increase expression |
| van Mil et al. [65] | miR-1 | Promote angiogenesis | Inhibit SPRED1 | Increase expression |
| Chen et al. [67] | Let-7 | Promote angiogenesis | Suppress AGO1, increase VEGF produce | Increase expression |
| Hu et al. [23] | miR-210 | Promote angiogenesis | Release angiogenic factors; decrease EFNA3 expression | Increase expression |
| Ghosh et al. [68] | miR-424 | Promote angiogenesis | Stabilize HIF-α | Increase expression |
| Yan et al. [69] | MIAT | Promote angiogenesis | Decrease miR-150-5p increase VEGF | Increase expression |

AGO1, argonaut 1; BMP, bone morphogenetic proteins; bFGF, basic fibroblast growth factor; DLL-4, notch ligand Delta-like 4; eNOS, endothelial nitric oxide synthase; GATA2, globin transcription factor binding protein 2; HIF-α, hypoxia-inducible factor-α; ITGA5, integrin α5; KLF4, Krüppel-like factor 4; MIAT, myocardial infarction-associated transcript; PAK4, pro-angiogenic p21 protein-Cdc42/Rac-activated kinase 4; PAI-1, plasminogen activator inhibitor-1; PDK-1, 3-phosphoinositide-dependent protein kinase-1; SPRED1, sprouty-related EVH1 domain-containing protein 1; SCF, stem cell factor; VEGF, vascular endothelial growth factor.

© 2016 The Authors.
However, a cluster of miRNAs increases angiogenesis after AMI. MiR-126 is considered a positive regulator of angiogenesis after AMI [62]. Huang et al. [63] reported that miR-126 overexpression upregulated vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF) and notch ligand Delta-like 4 (DLL4) in mesenchymal stem cells and thereby enhanced functional angiogenesis in the ischemic myocardium. Wang et al. [64] determined that the proangiogenic actions of miR-126 after MI were related to repressed expression of sprouty-related EVH1 domain-containing protein 1 (SPRED1), an intracellular inhibitor of angiogenic signalling. Furthermore, miR-1 also enhanced the angiogenic effects of progenitor cells by inhibiting SPRED1 expression [65].

Other miRNAs have been identified to promote angiogenesis after AMI. Let-7 plays an active role in the pathogenesis of MI [66]. Chen et al. [67] reported that hypoxia induced let-7 expression, which suppressed Argonaute 1 (AGO1) and increased VEGF to promote angiogenesis. Using an MI mouse model, Hu et al. [23] demonstrated that miR-210 improved angiogenesis by releasing angiogenic factors; overexpressing miR-210 resulted in the down-regulation of the angiogenic gene ENA-N43 and promoted angiogenesis. Ghosh et al. [68] reported that miR-322/424 was up-regulated after MI and hypoxia, and increased miR-424 targeted cullin-2 to stabilize hypoxia-inducible factor α isoforms and promote angiogenesis. Accordingly, enhancing the expression of the pro-angiogenic miRNAs might be a valuable therapeutic target in AMI.

Research has seldom discussed the roles of lncRNAs in angiogenesis after AMI. Previous findings have only reported that MIAT is related to angiogenesis, functioning as a competing endogenous RNA by sponging miR-150-5p in retinal endothelial cells to regulate VEGF levels. That is, MIAT overexpression acted as a sink for miR-150-5p, which in turn increased VEGF levels and promoted angiogenesis [69]. Further exploration of more lncRNAs involved in angiogenesis may determine whether they are potent factors that promote angiogenesis after AMI.

NcRNAs regulate fibrosis in infarct regions

Cardiac fibroblasts are activated and subsequently produce excessive extracellular matrix (ECM) proteins after MI, which ultimately impairs cardiac function and leads to interstitial fibrosis and remodelling of the heart. Accordingly, inhibiting excessive ECM secretion and deposition is an important therapeutic strategy for improving the prognosis of AMI. Several miRNAs have been implicated in the pathology of cardiac fibrosis after AMI (Fig. 3). Inhibiting the miR-34 family improved cardiac function in mice and attenuated pathological remodelling after MI. Bernardo et al. [70] reported that silencing entire miR-34 family protected the heart against pathological cardiac remodelling and improved cardiac function. The authors also found elevated collagen (Col) 1α1 gene expression in the infarct zone after MI in mice. However, MI mice treated with LNA-anti-miR-34 trended towards lower Col1α1 expression. Huang et al. [71] further demonstrated that inhibiting miR-34a reduced the severity of experimental cardiac fibrosis in mice after AMI, indicating that miR-34a plays a critical role in the progression of cardiac tissue fibrosis by directly inducing pro-fibrotic pathway transforming growth factor beta 1 (TGFβ1)/Smad4.

Furthermore, miR-208a and miR-21 were also involved in promoting cardiac fibrosis after MI. MI. MiR-208a was increased in rats with AMI, which significantly increased the area of myocardial fibrosis compared with the sham group. It was further believed that the cardiac fibrosis action induced by miR-208a was related to endoglin activation and β-myosin heavy chain expression [72]. MiR-21 is an important regulatory molecule in the pathogenic process of myocardial fibrosis after MI. MiR-21 was up-regulated in the border zone of the infarcted region after AMI in mice, which could increase the collagen content and lead to cardiac fibrosis, which was partially related to inhibition of transforming growth factor beta receptor III (TGFβRIII) expression [73]. Therefore, inhibiting these miRNAs may be a promising strategy for treating cardiac fibrosis after AMI.

However, some miRNAs inhibit cardiac fibrosis after AMI, and miR-29 is the most well-studied anti-fibrosis miRNA. van Rooij et al. [74] showed that miR-29 expression was down-regulated after MI, thereby inducing collagen overexpression and cardiac fibrosis. They also reported that the mechanism of collagen overexpression induced by low miR-29 levels was related to up-regulation of its targets Col1α1, Col1α2, Col1α3 and fibrillin 1 in the infarcted region. Melo et al. [75] also reported that swimming training improved ventricular function after MI in rats by improving cardiac miR-29a and miR-29c levels, thereby preventing COL1A1 and COL1A2 expression in the border region and remote myocardium of the infarcted left ventricle.

Additionally, several other miRNAs, including miR-101A, miR-24 and miR-711, also counteract cardiac fibrosis and attenuate the remodelling process after MI. MiR-101A is a novel identified anti-fibrotic miRNA that suppresses cardiac fibrosis and improves the impaired cardiac function in post-infarct rats, which involves the
underlying mechanism of inhibiting the c-fos/TGFβ1 and TGFβR1 pathways [76, 77]. MiR-24 was also down-regulated in mouse heart after MI. MiR-24 improved heart function and attenuated fibrosis in the infarct border zone of the heart 2 weeks after MI induced through intramyocardial injection of lentiviruses, which was related to the regulation of furin (a protease that controls latent TGFβ activation) and reduced TGFβ (a pathological mediator of fibrotic disease) secretion and Smad2/3 phosphorylation in cardiac fibroblasts [78]. Moreover, up-regulating miR-711 inhibited cardiac fibrosis in rats with MI, which was mainly related to the reduced COLI levels [79]. Therefore, these miRNAs act as regulators of cardiac fibrosis and represent potential therapeutic targets of tissue fibrosis after AMI.

Recently, IncRNAs were also studied in cardiac fibrosis after AMI. A recent study detected IncRNAs variation in mice 4 weeks after MI and found that at the peri-infarct region, 53 IncRNAs had been up-regulated by more than twofold and 37 IncRNAs has been down-regulated by over 0.5-fold. Meanwhile, NONMMU0222554 was identified as the most significantly up-regulated IncRNA and was positively correlated with six up-regulated genes involved in ECM-receptor interactions [80]. Furthermore, some IncRNAs were also related to cardiac fibrosis. For example, overexpression of H19 contributed to cardiac fibroblast proliferation and fibrosis [81]. LncRNA cardiac hypertrophy-related factor also regulates cardiac hypertrophy [82]. However, the pro-fibrotic function of these IncRNAs in MI has not been identified, and with further exploration, they may also be potential targets for treating AMI.

**LncRNA/circRNA–miRNA-mediated interaction**

Generally, miRNAs bind directly to their target mRNAs by complementary base pairing and trigger mRNA cleavage based on the degree of complementarity. MiRNAs regulate gene expression, mostly at the 3’ untranslated region, thereby decreasing mRNA translation and stability [83]. LncRNAs and circRNAs function as molecular regulators by determining gene expression from transcription to translation. More interestingly, IncRNAs and circRNAs both contain complementary binding sites to miRNAs and act as endogenous miRNA sponges; miRNAs in turn interact with mRNAs, serving as negative regulators of protein expression. Moreover, the regulatory mechanism of IncRNAs and circRNAs mainly focuses on acting as molecular sponges by binding to miRNAs and forming an LncRNA/circRNA–miRNA axis to regulate the expression of the related mRNAs and proteins [9].

As previously reported, CARL induces cardiac myocyte apoptosis by acting as an endogenous sponge and reducing miR-539 levels, which subsequently inhibits mitochondrial fission and apoptosis in the heart [45]. H19 binds directly to miR-103/107, repressing RIPK1 and RIPK3, negatively regulating FADD and reducing apoptosis [46]. Similarly, MIAT acts as a competing endogenous RNA sponge to miR-150-5p, regulating VEGF levels and endothelial cell function [69]. The circRNA CDR1as functioned as a miR-7a sponge in myocardial cells and regulated cardiomyocyte apoptosis after MI [49]. These findings demonstrate the critical mechanism in the miRNA regulatory networks, which are involved in the complex, competitive endogenous RNA network.

**Conclusion and clinical perspectives**

Recently, novel therapeutic approaches for AMI have received much attention, and numerous potential targets, especially ncRNAs, have been studied. Emerging data suggest that ncRNAs play important roles in several physiological and pathological processes in AMI. The best-studied ncRNAs are miRNAs; several miRNAs might be attractive candidates for improving recovery by controlling the pathological conditions of AMI. For example, several animal studies have demonstrated that miR-92a inhibitors reduce cardiomyocyte apoptosis and promote angiogenesis, thereby decreasing infarct size and improving prognosis after AMI. Apart from miRNAs, IncRNAs and circRNAs such as MIAT and CDR1as have emerged as potential regulators of AMI progression. However, these recently identified ncRNAs in AMI and their interactions have not been completely described. We analyzed the ncRNAs implicated in the processes of AMI to gain insight into their potential functions as therapeutic targets of AMI.

Although the evidence is convincing and indicates that manipulating ncRNA levels is efficient for reducing infarct area and for restoring left ventricular mass, as well as promoting functional recovery after AMI in animal models, the development of ncRNA therapy faces several challenges. Moreover, it is difficult to use the regulatory ncRNAs in the clinic in a short time. First, our understanding of the biology of ncRNAs is far from complete; this is especially true for IncRNAs and circRNAs, which are involved in more complex and wider functions by interacting with miRNAs. Next, targeting ubiquitously expressed ncRNAs may encounter challenges with respect to off-target effects and unwanted adverse effects in other cells or tissues. In addition, as gene therapy requires the use of vectors to some extent, the safety and efficacy still requires thorough evaluation. Accordingly, although ncRNAs have promising application prospects, they have not reached the stage that would allow easy clinical translation. In future research, some cases may require cell type-specific delivery strategies. Preclinical trials (such as the antagoniR anti-miR-122 for treating hepatitis C virus infection [84, 85]) for evaluating their safety and feasibility will aid the development of ncRNA therapeutics for AMI.

**Acknowledgements**

This work was supported by the grant from the National Natural Science Foundation of China (No. 81372117). This work was supported by the Fundamental Research Funds for the Central Universities of Central South University (No. 2016zzts132).

**Conflict of interest**

The authors reported no relationships that could be construed as a conflict of interest.
References

1. Orrego AM, Gustafsson AB. Cell death in the myocardium: my heart won’t go on. IUBMB Life 2013; 65: 651–6.

2. Cochin C, Shannon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013; 18: 1100–13.

3. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006; 15: R17–29.

4. Consortium IHGS. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431: 931–45.

5. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009; 23: 1494–504.

6. Doerks T, Copley RR, Schultz J, et al. Systematic identification of novel protein domain families associated with nuclear function. Genome Res. 2002; 12: 47–56.

7. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007; 101: 1225–36.

8. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009; 324: 1710–3.

9. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43: 904–14.

10. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long non-coding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22: 1775–89.

11. Chen Y, Li C, Tan C, et al. Circular RNAs: a new frontier in the study of human diseases. J Med Genet. 2016; 53: 359–65.

12. Ebbesen KS, Kjems J, Hansen TB. Circular RNAs: identification, biogenesis and function. Biochim Biophys Acta. 2016; 1859: 163–8.

13. Liu LF, Liang Z, Lv ZR, et al. MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. J Geriatr Cardiol. 2012; 9: 28–32.

14. Hul linger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15b protects against cardiac ischemic injury. Circ Res. 2012; 110: 71–81.

15. Li X, Zeng Z, Li Q, et al. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015; 6: 18289–44.

16. Fiedler J, Jazbutyte V, Kirchmair BG, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011; 124: 720–30.

17. Meloni M, Marchetti M, Garner K, et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther. 2013; 21: 1390–402.

18. Tony H, Meng K, Wu B, et al. MicroRNA-208a dysregulates apoptosis genes expression and promotes cardiomyocyte apoptosis during ischemia and its silencing improves cardiac function after myocardial infarction. Mediators Inflamm. 2015; 2015: 479123. DOI: 10.1155/2015/479123.

19. Iekushi K, Seeger F, Assmus B, et al. Regulation of cardiac microRNAs by bone marrow mononuclear cell therapy in myocardial infarction. Circulation. 2012; 125: 1765–73, S1–7.

20. Fan F, Sun A, Zhao H, et al. MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2. Curr Pharm Des. 2013; 19: 4865–73.

21. Wang K, Liu F, Zhou LY, et al. miR-874 regulates myocardial necrosis by targeting caspase-8. Cell Death Dis. 2013; 4: e709.

22. Eisenhardt SU, Weiss JB, Smolka C, et al. MicroRNA-155 aggravates ischemia-reperfusion injury by modulation of inflammatory cell recruitment and the respiratory oxidative burst. Basic Res Cardiol. 2015; 110: 32. DOI: 10.1007/s00395-015-0490-9.

23. Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010; 122: S124–31.

24. Yang X, Qin Y, Shao S, et al. MicroRNA-214 inhibits left ventricular remodeling in an acute myocardial infarction rat model by suppressing cellular apoptosis via the Phosphatase and Tensin Homolog (PTEN). Int Heart J. 2016; 57: 247–50.

25. Glass C, Singla DK. ES cells overexpressing microRNA-1 attenuate apoptosis in the injured myocardium. Mol Cell Biochem. 2011; 357: 135–41.

26. Glass C, Singla DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. Am J Physiol Heart Circ Physiol. 2011; 301: H5038–49.

27. Yang Q, Yang K, AY Li. Trimezzidine protects against hypoxia-reperfusion-induced cardiomyocyte apoptosis by increasing microRNA-21 expression. Int J Clin Exp Pathol. 2015; 8: 3735–41.

28. Yang Q, Yang K, Li A. microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/ Akt-dependent mechanism. Mol Med Rep. 2014; 9: 2213–20.

29. Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res. 2010; 87: 431–9.

30. Cheng Y, Liu X, Zhang S, et al. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol. 2009; 47: 5–14.

31. Dong S, Cheng Y, Yang J, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 2009; 284: 29514–25.

32. van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009; 17: 662–73.

33. Chen X, Zhang L, Su T, et al. Kinetics of plasma microRNA-499 expression in acute myocardial infarction. J Thorac Dis. 2015; 7: 890–6.

34. Wang J, Jia Z, Zhang C, et al. miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdc4d and PACS2. RNA Biol. 2014; 11: 339–50.

35. Li Y, Lu J, Bao X, et al. MiR-499-Sp protects cardiomyocytes against ischaemic injury via anti-apoptosis by targeting PDCD4. Oncotarget. 2016; 7: 35607–17.

36. Dakhilallah D, Zhang J, Yu L, et al. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart. J Cardiovasc Pharmacol. 2015; 65: 241–51.

37. Lu C, Wang X, Ha T, et al. Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling. J Mol Cell Cardiol. 2015; 69: 87–97.

38. Ding SL, Wang JX, Jiao JQ, et al. A pre-microRNA-149 (mir-149) genetic variation affects mir-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem. 2013; 288: 26865–77.

39. Zhang Y, Sun L, Xuan L, et al. Reciprocal changes of circulating long non-coding rnas zfas1 and cdr1as predict acute
43. Zangrando J, Salgado-Somoza A, Zhang L, et al. Myocardial Infarction-Associated Circular RNA Predicting Left Ventricular Dysfunction. J Am Coll Cardiol. 2016; 68: 1247–8.

44. Liu Z, Yan B, Liu N, et al. Circulating long noncoding RNA UCA1 as a novel biomarker of acute myocardial infarction. Biomed Res Int. 2016; 2079372. DOI: 10.1155/2016/2079372.

45. Zangrando J, Zhang L, Vausort M, et al. Identification of candidate long non-coding RNAs in response to myocardial infarction. BMC Genom. 2014; 15: 460.

46. Sanders LN, Schoenhard JA, Saleh MA, et al. MicroRNA-150 in human myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2015; 112: 679–84.

47. Wang K, Long B, Zhou LY, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 down-regulation. Nat Commun. 2014; 5: 3596. DOI: 10.1038/ncomms4596.

48. Wang K, Liu CY, Zhou LY, et al. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun. 2015; 6: 6779.

49. Wang K, Long B, Zhou LY, et al. The Circular RNA Cdr1as promotes myocardial infarction. Stem Cell Reports. 2014; 2: 605–16.

50. Wang K, Li R, Su YM, et al. MicroRNA-208a increases myocardial endoplasmic reticulum stress and cell survival. Int J Mol Med. 2016; 37: 1022.

51. Yao R, Ma Y, Du Y, et al. The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndrome. Cell Mol Immunol. 2011; 8: 486–95.

52. Liu X, Dong Y, Chen S, et al. Circulating MicroRNA-146a and MicroRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction. Cardiology. 2015; 132: 233–41.

53. Ibrahim AG, Cheng K, Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014; 2: 605–16.

54. Toldo S, Das A, Mezzaroma E, et al. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet. 2014; 7: 311–20.

55. Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014; 115: 668–77.

56. Bellera N, Barba I, Rodriguez-Sinovas A, et al. Single intracoronary injection of encapsulated antagonist-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc. 2013; 3: e000946.

57. Hinkel R, Penzofer D, Zhuiko S, et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013; 128: 1066–75.

58. Icli B, Wara AK, Moslehi J, et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. 2013; 113: 1304–13.

59. Kang HJ, Kang WS, Hong MH, et al. Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction. Cell Signal. 2015; 27: 2241–51.

60. Geng HH, Li R, Su YM, et al. The Circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression. PLoS One. 2016; 11: e0151753.

61. Sanders LN, Schoenhard JA, Saleh MA, et al. BMP antagonist gremlin 2 limits Infarction after myocardial infarction. Circ Res. 2016; 119: 434–49.

62. Liu Z, Ye P, Wang S, et al. MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction. Circ Cardiovasc Genet. 2015; 8: 11–20.
76. Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 2012; 126: 840–50.
77. Zhao X, Wang K, Liao Y, et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFbetaRI on cardiac fibroblasts. Cell Physiol Biochem. 2015; 35: 213–26.
78. Wang J, Huang W, Xu R, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med. 2012; 16: 2150–60.
79. Zhao N, Yu H, Yu H, et al. MiRNA-711-SP1-collagen-I pathway is involved in the anti-fibrotic effect of pioglitazone in myocardial infarction. Sci China Life Sci. 2013; 56: 431–9.
80. Qu X, Song X, Yuan W, et al. Expression signature of IncRNAs and their potential roles in cardiac fibrosis of post-infarct mice. Biosci Rep. 2016; 36: pii:e00337.
81. Tao H, Cao W, Yang JJ, et al. Long noncoding RNA H19 controls DUSPS/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. Cardiovasc Pathol. 2016; 25: 381–9.
82. Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 2014; 114: 1377–88.
83. Bartel DP. MicroRNAs Target Recognition and Regulatory Functions. Cell. 2009; 136: 215–33.
84. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368: 1685–94.
85. van der Ree MH, van der Meer AJ, de Bruijne J, et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 2014; 111: 53–9.